2024
A Mendelian randomization study of alcohol use and cardiometabolic disease risk in a multi‐ancestry population from the Million Veteran Program
Kember R, Rentsch C, Lynch J, Vujkovic M, Voight B, Justice A, Program M, Assimes T, Kranzler H. A Mendelian randomization study of alcohol use and cardiometabolic disease risk in a multi‐ancestry population from the Million Veteran Program. Alcohol Clinical And Experimental Research 2024 PMID: 39580711, DOI: 10.1111/acer.15445.Peer-Reviewed Original ResearchCoronary heart diseaseMR analysisMillion Veteran ProgramGenetic scoreAlcohol consumptionBody mass indexMendelian randomizationCardiometabolic diseasesVeteran ProgramAfrican AmericansAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) scoresEuropean AmericansHispanic AmericansAssociation of alcohol consumptionMultivariable MR analysisAssociated with CHD riskMendelian randomization studiesRisk of cardiometabolic diseasesAssociated with alcohol consumptionCardiometabolic disease riskIncidence of coronary heart diseaseObservational studyNested case-control studyReduced risk of cardiometabolic diseasesMulti-ancestry population
2023
Challenges in Estimating the Effectiveness of COVID-19 Vaccination Using Observational Data
Hulme W, Williamson E, Horne E, Green A, McDonald H, Walker A, Curtis H, Morton C, MacKenna B, Croker R, Mehrkar A, Bacon S, Evans D, Inglesby P, Davy S, Bhaskaran K, Schultze A, Rentsch C, Tomlinson L, Douglas I, Evans S, Smeeth L, Palmer T, Goldacre B, Hernán M, Sterne J. Challenges in Estimating the Effectiveness of COVID-19 Vaccination Using Observational Data. Annals Of Internal Medicine 2023, 176: m21-4269. PMID: 37126810, PMCID: PMC10152408, DOI: 10.7326/m21-4269.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccineRandomized trialsObservational studyCOVID-19 vaccinationDuration of protectionBooster vaccinationFirst doseTrial emulationNew virus variantsVaccinated personsEligible personsVaccine rolloutVaccinationTarget trialsVirus variantsTrialsVaccineTime-varying variablesBaselineRobust evidenceSingle trial approachRapid uptakePersonsConfoundersDose
2022
Mortality among Care Home Residents in England during the first and second waves of the COVID-19 pandemic: an observational study of 4.3 million adults over the age of 65
Schultze A, Nightingale E, Evans D, Hulme W, Rosello A, Bates C, Cockburn J, MacKenna B, Curtis HJ, Morton CE, Croker R, Bacon S, McDonald HI, Rentsch CT, Bhaskaran K, Mathur R, Tomlinson LA, Williamson EJ, Forbes H, Tazare J, Grint D, Walker AJ, Inglesby P, DeVito NJ, Mehrkar A, Hickman G, Davy S, Ward T, Fisher L, Green AC, Wing K, Wong AY, McManus R, Parry J, Hester F, Harper S, Evans SJ, Douglas IJ, Smeeth L, Eggo RM, Goldacre B, Leon DA. Mortality among Care Home Residents in England during the first and second waves of the COVID-19 pandemic: an observational study of 4.3 million adults over the age of 65. The Lancet Regional Health - Europe 2022, 14: 100295. PMID: 35036983, PMCID: PMC8743167, DOI: 10.1016/j.lanepe.2021.100295.Peer-Reviewed Original ResearchCare home residentsComparative mortality figureHome residentsMortality riskCOVID-19Care homesCOVID-19 mortality riskCare home populationUnderlying frailtyHome populationObservational studyMortality figuresNHS EnglandSecond waveOlder residentsCOVID-19 pandemicRiskMortalityPrivate homesCareWomenAdultsMenProtective measuresFirst wave
2021
Polypharmacy-associated risk of hospitalisation among people ageing with and without HIV: an observational study
Justice AC, Gordon KS, Romero J, Edelman EJ, Garcia BJ, Jones P, Khoo S, Re V, Rentsch CT, Tate JP, Tseng A, Womack J, Jacobson D. Polypharmacy-associated risk of hospitalisation among people ageing with and without HIV: an observational study. The Lancet Healthy Longevity 2021, 2: e639-e650. PMID: 34870254, PMCID: PMC8639138, DOI: 10.1016/s2666-7568(21)00206-3.Peer-Reviewed Original ResearchConceptsVeterans Aging Cohort StudyMedication countDrug-drug interactionsAntiretroviral therapyObservational studyPhysiological frailtyVeterans Affairs Health Services ResearchMore drug-drug interactionsRisk of hospitalisationRisk of admissionAging Cohort StudyHIV-1 RNANon-ART medicationsAdverse health outcomesNational InstituteHealth services researchAdditional medicationObserved medicationActive medicationCause mortalityMore medicationsCohort studyPrescription fillsHIV statusPrescription medicationsPharmacoepidemiology, Machine Learning, and COVID-19: An Intent-to-Treat Analysis of Hydroxychloroquine, With or Without Azithromycin, and COVID-19 Outcomes Among Hospitalized US Veterans
Gerlovin H, Posner DC, Ho YL, Rentsch CT, Tate JP, King JT, Kurgansky KE, Danciu I, Costa L, Linares FA, Goethert ID, Jacobson DA, Freiberg MS, Begoli E, Muralidhar S, Ramoni RB, Tourassi G, Gaziano JM, Justice AC, Gagnon DR, Cho K. Pharmacoepidemiology, Machine Learning, and COVID-19: An Intent-to-Treat Analysis of Hydroxychloroquine, With or Without Azithromycin, and COVID-19 Outcomes Among Hospitalized US Veterans. American Journal Of Epidemiology 2021, 190: 2405-2419. PMID: 34165150, PMCID: PMC8384407, DOI: 10.1093/aje/kwab183.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnti-Bacterial AgentsAzithromycinCOVID-19COVID-19 Drug TreatmentDrug Therapy, CombinationFemaleHospitalizationHumansHydroxychloroquineIntention to Treat AnalysisMachine LearningMaleMiddle AgedPharmacoepidemiologyRetrospective StudiesSARS-CoV-2Treatment OutcomeUnited StatesVeteransConceptsUS veteransCOVID-19Veterans Affairs Health Care SystemRecent randomized clinical trialsAdministration of hydroxychloroquineEffectiveness of hydroxychloroquineRisk of intubationEffect of hydroxychloroquineElectronic health record dataRandomized clinical trialsTreatment of patientsUS veteran populationCOVID-19 outcomesCoronavirus disease 2019Health record dataRigorous study designsHealth care systemSurvival benefitTreat analysisEarly therapyHospitalized populationClinical trialsObservational studyDisease 2019Hydroxychloroquine